A Phase 3 interventional study of INCA034176 in Chronic Graft-versus-host-disease, sponsored by Incyte Biosciences Japan GK. Active, not recruiting at 16 sites in Japan. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Incyte Biosciences Japan GK (part of Incyte Corporation) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome — 5 open to participants now, 9 under way, 3 of them phase 3. axatilimab · Bronchiolitis Obliterans Syndrome.
Among the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 3rd registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →5 of the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–17
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 12+
Incyte Corporation · Sites in United States, Australia, Austria and 10 more countries
Ages 12+
Syndax Pharmaceuticals · Sites in United States, Australia, Belgium and 13 more countries
Ages 2+
By country, each count listing its studies:
axatilimab: first FDA approval 2024 (NIKTIMVO). What it is approved for, and how studies give it, is on its page →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 3
First in 2018; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 50 across the 10 interventional studies. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 5 most frequent:
This study is registered under Incyte Biosciences Japan GK, one of the names counted as Incyte Corporation. Under that name alone:
Incyte Biosciences Japan GK is the lead sponsor of 6 studies on the registry; none are open to participants now.
12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation: 4 open now, 8 under way, 4 of them phase 3. Of 4 finished, 3 (75%) have results posted.
Among the 12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 6th registered.
Incyte Corporation’s Bronchiolitis Obliterans Syndrome studies by the year they started, since 2017.
2 of the studies testing axatilimab in Bronchiolitis Obliterans Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585774Phase 3Incyte CorporationA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2027-09-28 |
| NCT06843408Incyte CorporationA Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | 2027-01-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, from their registry updates:
Among Incyte Corporation’s 12 in Bronchiolitis Obliterans Syndrome:
This tab as a report to print or save as PDF → With an account.
This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ability to comprehend and willingness to sign a written ICF for the study.
Japanese participants who are recipients with active, , or recurrent cGVHD requiring systemic immune suppression despite at least 2 lines of prior systemic therapy.
Refractory disease is defined as meeting any of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Axatilimab at the protocol-defined dose.
Drug: INCA034176
IV infusion
Also known as: Axatilimab
Overall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
ORR was defined as the percentage of participants with a physician-assessed complete response (CR) or a physician-assessed partial response (PR), evaluated as defined by the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease (cGVHD). A participant was considered an objective responder if they had an overall response of CR or PR at any timepoint up to the beginning of Cycle 7. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.
Time frame: up to the end of Cycle 6 (up to 168 days)
Percentage of Participants With a ≥7-point Improvement in Modified Lee Symptom Scale (mLSS) Score
The mLSS is a 28-item instrument comprising 7 subscales, designed to assess the impact of cGVHD on a participant's symptoms. Participants were asked to indicate the degree of "bother" during the past 7 days due to symptoms in 7 domains (skin, eyes and mouth, breathing, eating and digestion, muscles and joints, energy, emotional distress) potentially affected by cGVHD. A mLSS responder is defined as a participant who achieved at least a 7-point improvement from baseline in the normalized mLSS score. This score is on a 0-100 scale, calculated as the average of the subscale scores.
Time frame: before Cycle 7 Day 1 (up to 168 days); during study (up to 12.8 months)
ORR, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
ORR was defined as the percentage of participants with a physician-assessed CR or a physician-assessed PR, evaluated as defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD. A participant was considered an objective responder if they had an overall response of CR or PR at any post-baseline visit. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.
Time frame: up to 12.8 months
Duration of Response (DOR) in Participants With a Response in the First 6 Treatment Cycles
Duration of response was defined as the time from the first response of either CR or PR until progression of cGVHD, start of another anti-GVHD treatment, or death from any cause, whichever was earlier. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. DOR was assessed for participants whose first CR or PR occurred during the first 6 treatment cycles. A response was followed until the response ended, regardless of whether the response ended during the first 6 treatment cycles or after Cycle 6.
Time frame: up to 13.8 months (maximum duration of treatment [12.8 months] plus 30 days)
Organ-specific Response Rate
Organ-specific response rate was defined as the percentage of participants with a CR or PR for the 9 individual organs based on the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (skin, eyes, mouth, esophagus, upper gastrointestinal (GI) tract, lower GI, liver, lungs, and joints and fascia) in participants with each corresponding organ involvement at baseline.
Time frame: up to 12.8 months
Percent Reduction in Average Daily Dose (or Equivalent) of Corticosteroids in the First 6 Treatment Cycles
Participants may have been taking a corticosteroid upon study entry. At the discretion of the investigator, the corticosteroid dose may have been tapered after the first 4 weeks of study drug administration for participants who achieved either a PR or CR. Percent reduction was calculated as the (\[difference between the baseline value and the post-baseline value\]/divided by the baseline value) x 100.
Time frame: up to the end of Cycle 6 (up to 168 days)
Percentage of Participants Who Discontinued Corticosteroid Use After Study Entry in the First 6 Treatment Cycles
Participants may have been taking a corticosteroid upon study entry. At the discretion of the investigator, the corticosteroid dose may have been tapered after the first 4 weeks of study drug administration for participants who achieved either a PR or CR.
Time frame: up to the end of Cycle 6 (up to 168 days)
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. For the purposes of analysis, all AEs were considered to be TEAEs unless the AE could unequivocally be defined as not treatment emergent.
Time frame: up to 13.8 months
Number of Participants With Any ≥Grade 3 TEAE
An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. For the purposes of analysis, all AEs were considered to be TEAEs unless the AE could unequivocally be defined as not treatment emergent. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to 13.8 months
Change From Baseline in Karnofsky/Lansky Performance Status
The Karnofsky/Lansky performance status allows participants to be classified as to their functional impairment on a scale from 0 to 100. The lower the score, the worse the survival for most serious illnesses. The score can be used to compare the effectiveness of different therapies and to assess the prognosis in individual participants. The Karnofsky scale is designed for participants aged 16 years and older, and the Lansky scale is designed for participants younger than 16 years. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: up to 13.8 months
Percentage of Participants Positive for Anti-drug Antibodies (ADAs)
Antibodies to axatilimab were evaluated in plasma samples collected from all participants.
Time frame: up to 12.8 months
INCA034176 Concentration
Plasma samples were collected for pharmacokinetic (PK) analysis.
Time frame: up to 12.8 months
| Milestone | Axatilimab 0.3 mg/kg Q2W IV |
|---|---|
| Started | 21 |
| Completed | 0 |
| Not completed | 21 |
| Withdrew: Ongoing | 19 |
| Withdrew: Lung transplantation | 1 |
| Withdrew: Physician decision | 1 |
ORR was defined as the percentage of participants with a physician-assessed complete response (CR) or a physician-assessed partial response (PR), evaluated as defined by the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease (cGVHD). A participant was considered an objective responder if they had an overall response of CR or PR at any timepoint up to the beginning of Cycle 7. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.
| percentage of participants | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| Overall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD | 71.4 (47.8 to 88.7) |
The mLSS is a 28-item instrument comprising 7 subscales, designed to assess the impact of cGVHD on a participant's symptoms. Participants were asked to indicate the degree of "bother" during the past 7 days due to symptoms in 7 domains (skin, eyes and mouth, breathing, eating and digestion, muscles and joints, energy, emotional distress) potentially affected by cGVHD. A mLSS responder is defined as a participant who achieved at least a 7-point improvement from baseline in the normalized mLSS score. This score is on a 0-100 scale, calculated as the average of the subscale scores.
| percentage of participants | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| mLSS reduction ≥7 points on or before Cycle 7 Day 1 | 45.0 (23.1 to 68.5) |
| mLSS reduction ≥7 points on study | 50.0 (27.2 to 72.8) |
ORR was defined as the percentage of participants with a physician-assessed CR or a physician-assessed PR, evaluated as defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD. A participant was considered an objective responder if they had an overall response of CR or PR at any post-baseline visit. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.
| percentage of participants | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| ORR, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD | 76.2 (52.8 to 91.8) |
Duration of response was defined as the time from the first response of either CR or PR until progression of cGVHD, start of another anti-GVHD treatment, or death from any cause, whichever was earlier. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. DOR was assessed for participants whose first CR or PR occurred during the first 6 treatment cycles. A response was followed until the response ended, regardless of whether the response ended during the first 6 treatment cycles or after Cycle 6.
| months | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| Duration of Response (DOR) in Participants With a Response in the First 6 Treatment Cycles | NA (NA to NA) |
Organ-specific response rate was defined as the percentage of participants with a CR or PR for the 9 individual organs based on the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (skin, eyes, mouth, esophagus, upper gastrointestinal (GI) tract, lower GI, liver, lungs, and joints and fascia) in participants with each corresponding organ involvement at baseline.
| percentage of participants | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| Skin | 30.8 (9.1 to 61.4) |
| Eyes | 0.0 (0.0 to 23.2) |
| Mouth | 61.5 (31.6 to 86.1) |
| Lower GI tract | 50.0 (1.3 to 98.7) |
| Liver | 100.0 (2.5 to 100.0) |
| Lungs | 18.2 (2.3 to 51.8) |
| Joints and fascia | 90.0 (55.5 to 99.7) |
Participants may have been taking a corticosteroid upon study entry. At the discretion of the investigator, the corticosteroid dose may have been tapered after the first 4 weeks of study drug administration for participants who achieved either a PR or CR. Percent reduction was calculated as the (\[difference between the baseline value and the post-baseline value\]/divided by the baseline value) x 100.
| percent reduction | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| Day 1 to ≤Day 28 | 0.00 ± 0.000 |
| Day 29 to ≤Day 56 | 0.00 ± 0.000 |
| Day 57 to ≤Day 84 | 0.98 ± 2.346 |
| Day 85 to ≤Day 112 | 4.02 ± 6.589 |
| Day 113 to ≤Day 140 | 11.31 ± 16.097 |
| Day 141 to ≤Day 168 | 17.47 ± 21.940 |
Participants may have been taking a corticosteroid upon study entry. At the discretion of the investigator, the corticosteroid dose may have been tapered after the first 4 weeks of study drug administration for participants who achieved either a PR or CR.
| percentage of participants | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| Percentage of Participants Who Discontinued Corticosteroid Use After Study Entry in the First 6 Treatment Cycles | 0.0 |
An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. For the purposes of analysis, all AEs were considered to be TEAEs unless the AE could unequivocally be defined as not treatment emergent.
| Participants | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 20 |
An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. For the purposes of analysis, all AEs were considered to be TEAEs unless the AE could unequivocally be defined as not treatment emergent. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| Number of Participants With Any ≥Grade 3 TEAE | 8 |
The Karnofsky/Lansky performance status allows participants to be classified as to their functional impairment on a scale from 0 to 100. The lower the score, the worse the survival for most serious illnesses. The score can be used to compare the effectiveness of different therapies and to assess the prognosis in individual participants. The Karnofsky scale is designed for participants aged 16 years and older, and the Lansky scale is designed for participants younger than 16 years. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| Baseline, Karnofsky performance status score (KPSS) | 87.8 ± 4.28 |
| Baseline, Lansky performance status score (LPSS) | 80.0 ± 10.00 |
| Change from baseline in KPSS at Cycle 2 Day 1 | 0.6 ± 4.16 |
| Change from baseline in LPSS at Cycle 2 Day 1 | 3.3 ± 5.77 |
| Change from baseline in KPSS at Cycle 3 Day 1 | -0.6 ± 4.29 |
| Change from baseline in LPSS at Cycle 3 Day 1 | 0.0 ± 0.00 |
| Change from baseline in KPSS at Cycle 4 Day 1 | 0.0 ± 5.00 |
| Change from baseline in LPSS at Cycle 4 Day 1 | 0.0 ± 10.00 |
| Change from baseline in KPSS at Cycle 5 Day 1 | -0.6 ± 5.56 |
| Change from baseline in LPSS at Cycle 5 Day 1 | -5.0 ± 7.07 |
| Change from baseline in KPSS at Cycle 6 Day 1 | -0.6 ± 5.56 |
| Change from baseline in LPSS at Cycle 6 Day 1 | -5.0 ± 7.07 |
| Change from baseline in KPSS at Cycle 7 Day 1 | -1.2 ± 6.97 |
| Change from baseline in LPSS at Cycle 7 Day 1 | -5.0 ± 7.07 |
| Change from baseline in KPSS at Cycle 8 Day 1 | 0.0 ± 5.55 |
| Change from baseline in LPSS at Cycle 8 Day 1 | -5.0 ± 7.07 |
| Change from baseline in KPSS at Cycle 9 Day 1 | 0.0 ± 5.55 |
| Change from baseline in LPSS at Cycle 9 Day 1 | 0.0 ± NA |
| Change from baseline in KPSS at Cycle 10 Day 1 | 1.5 ± 5.55 |
| Change from baseline in LPSS at Cycle 10 Day 1 | 0.0 ± NA |
| Change from baseline in KPSS at Cycle 11 Day 1 | 1.0 ± 5.68 |
| Change from baseline in LPSS at Cycle 11 Day 1 | 0.0 ± NA |
| Change from baseline in KPSS at Cycle 12 Day 1 | 0.0 ± 7.07 |
| Change from baseline in LPSS at Cycle 12 Day 1 | 0.0 ± NA |
| Change from baseline in KPSS at Cycle 13 Day 1 | 0.0 ± 8.16 |
| Change from baseline in KPSS at Cycle 14 Day 1 | -10.0 ± NA |
| Change from baseline in KPSS at end of treatment | -10.0 ± NA |
| Change from baseline in LPSS at end of treatment | 10.0 ± NA |
Antibodies to axatilimab were evaluated in plasma samples collected from all participants.
| percentage of participants | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| Percentage of Participants Positive for Anti-drug Antibodies (ADAs) | 23.8 |
Plasma samples were collected for pharmacokinetic (PK) analysis.
| nanograms per milliliter (ng/mL) | Axatilimab 0.3 mg/kg IV Q2W |
|---|---|
| INCA034176 Concentration | NA (NA to 13314) |
Collected over up to 13.8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axatilimab 0.3 mg/kg Q2W IV | 0/21 (0%) | 7/21 (33.3%) | 19/21 (90.5%) |
| Event | Axatilimab 0.3 mg/kg Q2W IV |
|---|---|
| AppendicitisInfections and infestations | 1/21 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/21 |
| COVID-19Infections and infestations | 1/21 |
| Cystitis viralInfections and infestations | 1/21 |
| DehydrationMetabolism and nutrition disorders | 1/21 |
| Large intestine polypGastrointestinal disorders | 1/21 |
| Pneumonia influenzalInfections and infestations | 1/21 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/21 |
| Spinal stenosisMusculoskeletal and connective tissue disorders | 1/21 |
| Urinary tract infectionInfections and infestations | 1/21 |
| Event | Axatilimab 0.3 mg/kg Q2W IV |
|---|---|
| NasopharyngitisInfections and infestations | 7/21 |
| InfluenzaInfections and infestations | 5/21 |
| DiarrhoeaGastrointestinal disorders | 4/21 |
| HeadacheNervous system disorders | 4/21 |
| Oedema peripheralGeneral disorders | 4/21 |
| PruritusSkin and subcutaneous tissue disorders | 4/21 |
| BronchitisInfections and infestations | 3/21 |
| ConstipationGastrointestinal disorders | 3/21 |
| Alanine aminotransferase increasedInvestigations | 2/21 |
| AnaemiaBlood and lymphatic system disorders | 2/21 |
| Age, Continuous(years) | Axatilimab 0.3 mg/kg Q2W IV |
|---|---|
| Mean | 41.9 ± 19.64 |
| Sex: Female, Male(Participants) | Axatilimab 0.3 mg/kg Q2W IV |
|---|---|
| Female | 8 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Axatilimab 0.3 mg/kg Q2W IV |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 21 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Axatilimab 0.3 mg/kg Q2W IV |
|---|---|
| Asian | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Jul 2024 to primary completion in Aug 2025, 12 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 30 phase 3 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axatilimab
Bronchiolitis Obliterans Syndrome →